Amilsulpride versus imipramine and placebo in dysthymia and major depression

Journal of Affective Disorders

Volumn 43, Issue 2, 1997, Pages 95-103

  Lecrubier, Y ^a   Boyer, P ^a   Turjanski, S ^b   Rein, W ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SANOFI   (France)

Author keywords

amisulpride; depression; dysthymia; placebo controlled study; treatment

Indexed keywords

AMISULPRIDE; BENZODIAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; HYPNOTIC AGENT; IMIPRAMINE; LAXATIVE; ANTIDEPRESSANT AGENT; DRUG DERIVATIVE; SULPIRIDE; SULTOPRIDE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DYSTHYMIA; FEMALE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THIRST; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA; AGED; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIPRAMINE; MALE; MIDDLE AGED; SULPIRIDE;

EID: 0031110985     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(96)00103-6     Document Type: Article

References (26)

1. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn revised. APA, Washington, DC.
2. Andreasen, N.C. (1983) The scale for assessment of negative symptoms (SANS). University of Iowa.
3. Andreasen, N.C. (1990) Positive and negative symptoms: historical and conceptual aspects. In: Andreasen, N.C. (Eds.), Schizophrenia: Positive and Negative Symptoms and Syndromes. Modern Problems of Pharmacopsychiatry. Karger, Basel, Vol. 24, pp. 1-43.
4. Bobon, D. (Ed.) (1983) The AMDP-System in Pharmacopsychiatry. Karger, Basel.
5. Boyer, P., Puech, A.J. (1987) Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools. Psychiatry and Psychobiology 2, 296-305.
6. Boyer, P., Lecrubier, Y., Puech, A.J., Dewally, J., Aubin, F. (1995) Treatment of negative symptoms in schizophrenia with amisulpride. British Journal Psychiatry 166, 68-72.
7. Derogatis, L.R., Lipman, R.S., Rickels, K., Uhlenhuth, E.H., Covi, L. (1974) The Hopkins Symptom Checklist (HSCL). In: Pichot P. (Eds.), Psychological Measurements in Psychopharmacology. Modern Problems in Pharmacopsychiatry. Karger, Basel, Vol. 7, pp. 79-111.
8. Hellerstein, D.J., Janowitch, P., Rosenthal, J., Samstag, L.W., Maurer, M., Kasch, K., Burrows, L., Poster, M., Cantillon, M., Winston, A. (1993) A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. American Journal Psychiatry 150, 1169-1175.
9. Kocsis, J.H., Frances, A.J., Voss, C., Mann, J.J., Mason, B.J., Sweeney, J. (1988) Imipramine treatment for chronic depression. Archives of General Psychiatry 45, 253-257.
10. Lapierre, Y., Ravindaran, A., Bakish, D. (1994) Serotoninergic agents in primary dysthymia. Neuropsychopharmacology 10, 299S.
11. Lecrubier, Y., Puech, A.J., Aubin, F., Boyer, P., Deyrieux, B. (1988) Improvement by amisulpride of the negative syndrome in non-psychotic subjects: a preliminary study. Psychiatry and Psychobiology 3, 329-333.
12. Lecrubier, Y., Pedarriose, A.M., Payan, C., Schmid-Burgk, W., Stabl, M., a Study Group (1995). Moclobemide versus clomipramine in non-melancholic, non-psychotic major depression. Acta Psychiatrica Scandinavica 92, 260-5.
13. Lipman, R.S. (1982) Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacology Bulletin 18, 69-77.
14. Loo, H., Poirier-Littré, M.F., Fleurot, O., Theron, M., Rein, W. (1996) Amisulpride versus placebo in the long-term treatment of negative schizophrenia. British Journal of Psychiatry (in press).
15. Montgomery, S.A. and æsberg, M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
16. National Institute of Mental Health (1976a) CGI, Clinical Global Impressions. In: Guy, W. (Eds.), ECDEU, Assessment Manual for Psycho-pharmacology (Rev), Rockville, Maryland, pp. 217-222.
17. National Institute of Mental Health (1976b) AIMS, Abnormal Involuntary Movement Scale. In: Guy, W. (Eds.), ECDEU Assessment Manual for Psychopharmacology (Rev), Rockville, Maryland, pp. 534-537.
18. Paillère-Martinot, M.L., Lecrubier, Y., Martinot, J.L., Aubin, F. (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. American Journal of Psychiatry 152, 130-33.
19. Paykel, E.S., Rowan, P.R., Parker, R.R. (1982) Response to phenelzine and amitriptyline in some types of depressed outpatients. Archives of General Psychiatry 39, 1041-1049.
20. 3 receptors. Neuropsychopharmacology 10, 242S.
21. Seivewright, N., Tyrer, P. (1990) Relationship of dysthymia to anxiety and other neurotic disorders. In: Burton, S.W. and Akiskal, H.S. (Eds.), Dysthymic Disorder. Gaskell, London, pp. 24-36.
22. Techar, C., Fischer-Cornelssen, K., Akessou, H.O. (1981) Bromocriptine as antidepressant: double-blind comparative study with imipramine in psychogenic and endogenous depression. Current Therapeutic Research 30, 830-842
23. Versiani, M. (1994) Pharmacotherapy of dysthymia: a controlled study with imipramine, moclobemide or placebo. Neuropsychopharmacology 10, 299S.
24. Widlöcher, D. (1983) Le Ralentissement Dépressif. PUF, Paris.
25. Willner, P. (1995) Dopaminergic mechanisms in depression and mania. In: Bloom, F.E. and Kupfer, D.J. (Eds.), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp. 921-31.
26. Zung, W. (1983) Review of placebo-controlled trials with bupropion. Journal of Clinical Psychiatry 44, 104-114.